Cargando…

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524374/ https://www.ncbi.nlm.nih.gov/pubmed/26251591 http://dx.doi.org/10.2147/COPD.S82829

Ejemplares similares

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
por: Wang, Chen, et al.
Publicado: (2015)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Publicado: (2014)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
Publicado: (2017)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Pulmonary hemodynamic profile in chronic obstructive pulmonary disease [Corrigendum]
Publicado: (2015)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Annual Body Weight Change and Prognosis in Chronic Obstructive Pulmonary Disease [Corrigendum]
Publicado: (2022)

Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]
Publicado: (2019)

Electronic health records and improved nursing management of chronic obstructive pulmonary disease [Corrigendum]
Publicado: (2015)

Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population [Corrigendum]
Publicado: (2016)

High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study [Corrigendum]
Publicado: (2019)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022)

Corrigendum to “Zeaxanthin: Review of Toxicological Data and Acceptable Daily Intake”
por: Edwards, James A., et al.
Publicado: (2019)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Once We Find Grade III Meconium Stained Amniotic Fluid, Must We Act as Early as Possible? [Corrigendum]
Publicado: (2023)

Aerobic Exercise Alleviates Inflammation, Oxidative Stress, and Apoptosis in Mice with Chronic Obstructive Pulmonary Disease [Corrigendum]
Publicado: (2021)

Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy [Corrigendum]
Publicado: (2021)

Corrigendum to air pollution and mortality in patients with chronic obstructive pulmonary disease: a cohort study in South Korea
Publicado: (2023)

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
por: Beeh, Kai M, et al.
Publicado: (2012)

Corrigendum to “Assessment of Bone Mineral Density in Male Patients with Chronic Obstructive Pulmonary Disease by DXA and Quantitative Computed Tomography”
por: Fountoulis, George, et al.
Publicado: (2018)

Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
Publicado: (2017)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Corrigendum to “The Efficacy and Safety of Chinese Herbal Decoction in Type 2 Diabetes: A 5-Year Retrospective Study”
por: Tian, Jiaxing, et al.
Publicado: (2017)

Corrigendum to “Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada”
por: Thanh, Nguyen Xuan, et al.
Publicado: (2019)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
por: Olivares, José Manuel, et al.
Publicado: (2021)

Corrigendum: An Increased Proportion of Apoptosis in CD4(+) T Lymphocytes Isolated from the Peripheral Blood in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Ju, Jinyung
Publicado: (2018)

Corrigendum: Moderate and Deep Hypothermia Produces Hyporesposiveness to Phenylephrine in Isolated Rat Aorta
por: Cho, Jun Woo, et al.
Publicado: (2014)

Daily Consumption of the Collagen Supplement Pure Gold Collagen(®) Reduces Visible Signs of Aging [Corrigendum]
Publicado: (2020)

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Corrigendum to “Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea”
por: Wang, Xiaoya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a63gv8s8an71c9kcd6vol67ia5